Eculizumab for severe kidney and blood clotting emergencies in adults
Part of Blood & lymphatic, Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial studies eculizumab, a targeted blood-clotting and immune system medicine, for adults hospitalized with hypertensive emergency–associated hemolytic uremic syndrome (a serious condition affecting kidneys and blood). It aims to see whether the drug can improve outcomes after this life-threatening event.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You were hospitalized for hypertensive emergency–associated hemolytic uremic syndrome within the last 10 days.
- You have severe high blood pressure plus signs of blood cell damage (anemia/low platelets/abnormal tests or blood smear changes) and usually kidney injury or organ symptoms.
- You can use effective birth control during the study and for at least 5 months after the last dose, if you can become pregnant.
- You are able to sign written informed consent and understand the study as required by the team.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests the drug ravulizumab for people with aHUS (a rare blood and kidney condition). It aims to see if the drug can help improve blood counts and kidney function.
This trial tests if eculizumab can prevent antibody-mediated rejection in people receiving a kidney transplant from a donor with a different blood type (ABO-incompatible). Eligible participants have end-stage renal disease and are scheduled for this type of transplant.
This trial tests three study drugs (called monoclonal antibodies) in people with end-stage kidney disease who are on hemodialysis. The goal is to see if these drugs are safe and how they affect your body while you're on dialysis.
This study tests a new medicine called INM004 in children with STEC-HUS, a serious illness that damages the kidneys and blood cells. It may help speed up recovery and prevent complications.
This trial tests whether eculizumab can safely help people with a serious blood vessel complication called TA-TMA after a stem cell transplant. You may be eligible if you have high-risk features and haven't improved with initial care.
This study looks at how rare gene mutations may explain atypical HUS (aHUS) and how that could guide more personalized treatment. It mainly involves people who have had aHUS affecting blood counts and kidneys.
Hear when a new Hypertensive Emergency-associated Hemolytic Uremic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.